Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 16/20 | 0.52 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754333 | 0.91 | CRHR1 (0.52) | CRHR1RORCMAOBADORA1ADORA3 | |
| SCHEMBL3753551 | 0.83 | CRHR1 (0.47) | CRHR1MAOBADORA1ADORA3 | |
| SCHEMBL3754133 | 0.83 | CRHR1 (0.50) | CRHR1MAOBADORA1ADORA3 | |
| SCHEMBL3758025 | 0.82 | CRHR1 (0.58) | CRHR1MAOB | |
| SCHEMBL4091510 | 0.79 | CRHR1 (0.55) | CRHR1MAOBADORA1ADORA3 | |
| SCHEMBL3751351 | 0.79 | CRHR1 (0.62) | CRHR1MAOBADORA3 | |
| SCHEMBL3758926 | 0.79 | CRHR1 (0.58) | CRHR1MAOB | |
| SCHEMBL3751171 | 0.77 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL3734143 | 0.77 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL3758841 | 0.77 | CRHR1 (0.45) | CRHR1MAOBADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | CRHR1 1/4885RORC 599/4885MAOB 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.